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Abstract
Background: Treatment guidelines for Clostridioides difficile infection (CDI) were updated by
the Infectious Disease Society of America (IDSA) & the Society for Healthcare Epidemiology of
America (SHEA) in 2017 making various modifications, most notably for disease severity &
treatment recommendations. Our objectives were to assess Connecticut medical providers’
concordance (2017-2019) to the 2017 SHEA/IDSA clinical treatment guidelines. The effect of
guideline concordance on the risk of CDI recurrence was also assessed.
Methods: Using data from the Connecticut Emerging Infections Program’s CDI surveillance in
New Haven County, severity & concordance were defined for CDI cases. For severity, white
blood cell count >15,000 & presence of megacolon and/or ileus were used. Concordant treatment
was defined as receiving the recommended first-line antibiotic (vancomycin for adult patients,
vancomycin or metronidazole for pediatric patients) for exactly 10 days. In univariate &
multivariate analyses, significance was determined by a p-value of <0.05.
Results: Of the 1,216 New Haven County incident cases eligible for the study (50.7%) from
2017 - 2019, an overall concordance of 23.0% was identified, increasing from 10.0% in 2017 to
36.9% in 2019. Concordance with initial choice of first line treatment increased from 40.2% in
2017 to 80.8% in 2019. Overall concordance was highest for cases with fulminant disease
(62.2%). The recurrence rate was 11.2% & was highest for patients with non-severe disease &
older age but was not significantly associated with treatment concordance.
Conclusion: From 2017 through 2019, CDI treatment in New Haven County increasingly was
concordant with the updated 2017 IDSA/SHEA guidelines, but as of 2019, the overall level was
still low except for those with severe disease. Although concordance with treatment did not
affect recurrence risk, close attention should be paid by medical providers to patients who are
classified as non-severe and/or elderly as they are at an increased risk for recurrence.
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Figure
Figure 1: Concordance with selected treatment criteria by year, 2017-2019
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Background:
CDI is a well-known cause of healthcare-associated (HA) infectious diarrhea, surpassing
Staphylococcus aureus as the most common cause for hospital-acquired infections.1 Surveillance
of CDI in the last decade has also revealed the rise of community-acquired cases (CA), shifting
public health interest towards understanding their causes.2 The national burden of CDI was
estimated in 2011 to be 293,300 HA-CDI cases, 159,700 CA-CDI cases and 29,300 deaths per
year.3 To reduce the morbidity and mortality of CDI cases, the Society for Healthcare
Epidemiology of America (SHEA) and the Infectious Diseases Society of America (IDSA)
routinely revise their national guidelines for CDI treatment based on emerging CDI
treatment/diagnostic data.
With a growing evidence base for the effectiveness of vancomycin treatment,4 5 the 2017
IDSA/SHEA guidelines were created to update the 2010 guidelines in no longer recommending
metronidazole as a first-line treatment option, instead encouraging vancomycin or fidaxomicin as
a first-line alternative.6 Secondly, the definition of disease severity changed: ‘mild/moderate’
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became ‘non-severe’, ‘severe’ remained the same, and ‘severe (complicated)’ became
‘fulminant’. For non-severe as well as severe cases, vancomycin 125mg given orally four times
daily for 10 days or fidaxomicin 200mg given orally twice daily for 10 days is recommended.
Vancomycin 500mg given orally four times daily, or by nasogastric tube in rare instances, is
recommended for fulminant cases.7
While the 2017 guidelines aim to incorporate the newer evidence base, there is concern
about medical provider concordance with these revisions, which is likely affected by timely
dissemination of these changes.8 9 Assessing concordance of CT medical providers with these
guidelines will identify differences in treatment patterns as well as clinical outcomes, and help
identify consequences, such as recurrent CDI, in cases where discordance is identified.
The CT Emerging Infections Program (CT-EIP) has been conducting enhanced
surveillance for CDI since 2011 in New Haven County. A previous study using data from these
surveillance efforts examined concordance with the previous 2010 IDSA/SHEA treatment
guidelines.10 This previous study looked at the unadjusted association between concordant care
and CDI recurrence and did not find any significant association. The objectives of this study
were to assess Connecticut medical providers’ concordance (2017-2019) to the 2017
SHEA/IDSA clinical treatment guidelines for CDI by assessing concordance of their prescribed
CDI treatment regimen with the 2017 guidelines. We focused specifically on the first-line
treatment prescribed and its duration to define concordance. Once concordance was assessed, we
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highlighted changes in concordance from this study with 2013-2016 Connecticut data collected
by Martinez et al. (2018) which examined concordance with the 2010 guidelines.11 Lastly, the
adjusted association of concordance on the risk of CDI recurrence was assessed, identifying the
effect of potential confounders on the risk of recurrent CDI, a step not taken in the previous
study.

Methods:
As a CDC-funded program with a protocol that underwent ethical review by the CDC,
the CDI surveillance program of the Emerging Infection Programs covers 35 counties in 10
states, capturing more than 12 million people in 2017.12 The CT-EIP CDI surveillance system
encompasses New Haven County, Connecticut. Laboratories serving New Haven County report
all positive C. difficile tests to CT-EIP staff. A CDI case was defined as a C. difficile-positive
stool test (toxin or molecular assay) from a person ≥1 year old who had no positive tests in the
prior 8 weeks.13 Cases were designated into epidemiologic classifications: healthcare facilityonset (HCFO), community-acquired (CA), or community onset-healthcare facility-associated
(CO-HCFA). A case was classified as HCFO if the CDI was healthcare facility-onset CDI
(positive stool collected more than three days after admission) from either a hospital or long-term
care facility.14 A case was classified as community-onset (CO) if the positive stool was collected
in an outpatient setting or within the three days of hospital admission. Of cases that were
classified as CO, those that did not have documentation of admission to a healthcare facility in
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the preceding 12 weeks of their stool were designated as CA and all other CO cases were
considered CO-HCFA.15
For this study, each CDI case was classified by clinical disease severity broken down into
3 categories (non-severe, severe, and fulminant). Following the 2017 SHEA/IDSA clinical
definitions, non-severe CDI cases were defined as having a white blood cell count of ≤15,000
/µl; severe cases were defined as having a white blood cell count of >15,000 /µl; and fulminant
cases were defined as having the presence of a toxic megacolon and/or ileus, regardless of white
blood cell count.16
For 2017 SHEA/IDSA guideline concordance, i.e., ‘guideline concordant care’, treatment
was assessed by two factors: the duration of treatment and the concordant antibiotic prescribed.
Duration of treatment was defined by the specific duration that the healthcare provider ordered.
Three possible scenarios explain how these durations were captured by EIP staff: 1. If a patient
was hospitalized for the entire prescribed treatment period, the electronic patient chart was
consulted. 2. If a patient was hospitalized for a portion of the prescribed treatment period, the
electronic patient chart and the discharge summary, which represents medication administered in
the hospital and medication prescribed after discharge, were consulted. 3. If the patient was not
hospitalized and sought care from their outpatient provider or went to an emergency department
or urgent care, the electronic order containing the prescribed treatment period, from their
provider in the given care setting, was consulted.
First-line treatment was classified as either the sole antibiotic prescribed for the first-line
treatment or the treatment given for the longest duration, if two treatments were noted in the
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chart review. Of cases that had two treatments of equal duration, first-line treatment was
designated as a combination. Treatment dosage, route of administration and frequency of dosing
(i.e., twice daily, every six or eight hours) was not assessed due to these clinical variables being
dropped in 2018 and 2019 CT-EIP data collection. For pediatric patients, guideline concordance
care was denoted as taking vancomycin or metronidazole for a 10-day duration regardless of
severity. For adult patients, guideline concordant care for non-severe and severe CDI cases was
defined as taking vancomycin or fidaxomicin for a 10-day duration, and vancomycin for
fulminant cases. Assessment of concordance in fulminant cases did not factor in treatment
duration as the 2017 SHEA/IDSA guidelines do not specify duration. Therefore, any fulminant
cases treated with vancomycin were deemed guideline concordant. Since concordant duration is
noted as strictly 10 days by the 2017 IDSA/SHEA guidelines, treatment duration greater than or
less than 10 days was deemed guideline discordant.
For analysis, cases with missing laboratory and treatment data were removed. Unadjusted
associations with concordant care and study variables, as well as recurrent CDI and study
variables were calculated for the adult study sample (≥18 years old) due to differences in
treatment recommendations for pediatric and adult patients. Finally, a multivariable logistic
regression of this sample was created using backwards elimination with the outcome of recurrent
CDI, the main predictor (guideline discordant care), and potential confounders.

Results:
Overall Study
Of the 2,399 New Haven County incident cases from 2017 - 2019, 1,232 (51.4%) had
complete laboratory and clinical characteristics to identify case severity and concordance. Cases
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with complete data compared to those who were excluded were more likely to be male, older,
non-Hispanic White or Black , HCFA or CO-HCFO, have underlying conditions and antecedent
antibiotic use. (Table 1). Of the 1,232 cases that had complete laboratory and clinical
characteristics, 16 who were taking the concordant form of treatment died before reaching the
concordant duration of treatment. These 16 cases were deemed ineligible for the study; the 1,216
cases who had complete data were used for analysis.
Of these 1,216 cases, 280 (23.0%) had guideline concordant care. Of all 2017 cases, 39
cases (10.0%) were guideline concordant. In 2019, 136 cases (36.9%) were guideline
concordant, an average increase in concordance of 13.5% per year over the three-year period.
Guideline concordant antibiotics increased from 157 cases (40.2%) in 2017 to 298 cases (80.8%)
in 2019, an average increase of 20.3% in the concordant initially prescribed antibiotic per year
over the three-year period. Of cases prescribed the concordant antibiotic, the concordant duration
of treatment increased from 39 cases (24.8%) in 2017 to 136 cases (45.6%) in 2019, an average
increase of 10.4% in the concordant duration of treatment per year over the three-year period
(Figure 1).
Table 2 shows the description of the study by year, including data from 2013-2016. The
2017-2019 total guideline concordance of 23.0% was more than twice as high as the 2013-2016
total guideline concordance of 8.7% which followed the 2010 SHEA/IDSA guidelines.17 Firstline treatment with vancomycin increased with each subsequent year from 2017-2019, with 292
cases (79.1%) receiving vancomycin in 2019. First-line treatment with metronidazole decreased
with each subsequent year from 2017-2019, with 72 cases (19.5%) receiving metronidazole in
2019. Further, Table 3 delineates the specific frequencies of duration (by days) for the study,
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which included the 16 cases who died before they could get 10 days of treatment. A total of
32.8% of patients getting vancomycin received it for 10 days. For those receiving metronidazole,
20.5% received it for 10 days. (Table 3).

Pediatric Cases
Of the 1,216 cases, there were 21 pediatric cases (<18 years old). Of these, 17 (81.0%)
were denoted as non-severe, one case (4.8%) as severe, and three cases (14.3%) as fulminant.
Twelve (12) cases (57.1%) received concordant treatment, a significantly higher proportion than
for adults (268, 22.4%) (P<0.001). Overall, 14 of the cases (66.7%) were epidemiologically
classified as CA, six cases (28.6%) were CO-HCFA, and one case (4.8%) was HCFO. One case
(4.8%) had recurrent CDI.

Adult Cases
Table 4 shows the distribution of adult cases by severity of CDI and selected
characteristics. Of the 1,195 adult cases (≥18 years old) with complete data, 790 (66.1%) were
classified as non-severe, 368 (30.8%) as severe, and 37 cases (3.1%) as fulminant. Statistically
significant associations noted include: guideline concordant care and severity, with fulminant
cases having the highest proportion of guideline concordant care (62.2%); age, both as a
continuous and categorical variable, and severity, with fulminant cases as having the highest
average age (72.57 ± 15.33) and highest percentage of those aged 65-74 years (35.1%), 75-84
(21.6%), and ≥85 (24.3%); epidemiologic classification and severity, with non-severe having the
highest percentage of CA (53.8%), severe as having the highest percentage of CO-HCFA
(39.4%), and fulminant having the highest percentage of HCFO (21.6%); and any previous
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antibiotic use and severity, with non-severe having the highest percentage of previous antibiotic
use (31.7%) (Table 4).
Table 5 shows the associations in adults between guideline care and study variables.
Without adjusting for confounding, the odds of having concordant care progressively increased
from 2017 to 2019. In 2018, it was 3.00 times higher than 2017 (95% CI; 1.98, 4.54), and in
2019 it was 5.95 times higher (95% CI; 3.94, 8.99). The odds of having concordant care in
fulminant cases was 5.57 times the odds of having concordant care for non-severe cases (95%
CI; 2.81, 11.04); and in severe cases was 0.73 times the odds of having concordant care in nonsevere cases (95% CI; 0.53, 1.00) (Table 5).
Table 6 shows the unadjusted association of having recurrent disease with study
demographic and treatment variables in adults from 2017-2019. First noted in Table 2, there
were 240 recurrent CDI cases in 2013-2016 (15.9% of 2013-2016 cases); and a reduced
frequency of 136 recurrent CDI cases in 2017-2019 (11.2% of 2017-2019 cases).18 For these 136
recurrent cases, the risk of having recurrent CDI was lower after receiving guideline nonconcordant care (the main predictor) than the risk after receiving guideline concordant care
(OR=0.81), although not statistically significant (Table 6). The risk for severe cases was lower
than for non-severe cases (OR=0.65, 95% CI; 0.43, 0.99), and was even lower for fulminant
cases (OR= 0.39, 95% CI; 0.09, 1.65). Risk increased with each increasing age group compared
to the 18-44 age group, with the highest risk of having recurrent CDI for those ≥85 years old
(OR=2.45, 95% CI; 1.11-5.38). Due to this increasing directionality in the age group categorical
variable, age was modeled as continuous in the multivariable logistic regression model.
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Table 7 shows the results of multiple regression modeling for predictors of recurrent CDI.
Adjusting for potential confounding, the risk of having recurrent CDI for discordant care
remained lower than that for concordant care (OR=0.80), but this finding was not statistically
significant. The risk of having recurrent CDI increased by 1.02 for each year of age (95% CI;
1.01, 1.03). As in the unadjusted analysis, the risk of having recurrent CDI decreased with
increasing disease severity: for severe cases it was approximately two-thirds that for non-severe
cases (OR=0.63, 95% CI; 0.41, 0.95); and for fulminant cases was a third that of non-severe
cases, a difference which in the multiple regression model was not statistically significant.
Table 8 offers supplementary considerations to the role of treatment duration in reducing
risk of CDI recurrence. The duration variable was modeled into further permutations and
unadjusted ORs were created with the outcome of CDI recurrence. While these ORs changed
based on the new permutations of duration, no significant findings could be drawn for either
vancomycin or metronidazole first-line treatment.

Discussion:
To the best of our knowledge, this is the largest geographic-based prospective
surveillance study evaluating prescribing practices for CDI. Other studies are either retrospective
or single center, and more limited in scope. This study had a number of notable findings.
Guideline concordant care in CDI cases from 2017-2019 increased with each subsequent year.
Guideline concordant care increased as case severity increased. Treatment concordance,
however, was not significantly associated with CDI recurrence. Controlling for all variables, a
non-severe epidemiologic classification and increasing age increased the probability of
recurrence.
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Ten (10.0) percent of CDI cases in 2017 were guideline concordant while 36.9% of CDI
cases in 2019 were guideline concordant. Overall 2017 SHEA/IDSA guideline treatment
concordance for CDI cases in New Haven County was very low in 2017, but the increase in
concordance with each subsequent year is encouraging. Our findings suggest that any change to
treatment guidelines will not result in immediate uptake of the amendments and will require at
least a multi-year period for change to be adopted by a majority of Connecticut providers. We
did not systematically collect data on rationales behind Connecticut providers’ decisions to
prescribe therapy inconsistent with treatment guidelines, but a small minority commented in the
patient chart that the patient was allergic to first-line treatment or insurance providers did not
cover vancomycin or fidaxomicin; this led to use of metronidazole as insurance coverage barriers
are significant for vancomycin use which is not universally covered by insurance companies.19
The proportion of cases with guideline concordant care increased with each subsequent
degree of severity in cases, and the proportion of recurrent CDI decreased with each subsequent
degree of severity in cases. This follows that cases that require more medical attention, severe
and more so fulminant cases, receive more aggressive treatment regimens, reducing both
discordance and potential risk for treatment failure. The highest proportion of CA cases were
non-severe; the CO-HCFA or HA cases may be more likely to be sicker at baseline because they
were recently hospitalized or in contact with healthcare than the CA cases.
Guideline concordant care was not significantly associated with recurrent CDI,
suggesting that the first-line antibiotic recommendation of vancomycin does not have a
significant effect on CDI recurrence compared to other antibiotics, mainly, metronidazole. These
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findings are consistent with Martinez et al. (2018) as well as other evidence, including Stevens et
al. (2017) and Johnson et al. (2014) which are frequently referenced regarding first-line
treatment options of CDI. In a retrospective cohort study of >45,000 patients, Stevens et al.
(2017) found that the recurrence rates of CDI among cases using vancomycin compared to cases
using metronidazole for first-line treatment were similar. 20 The study concluded that the use of
vancomycin is recommended over metronidazole for first-line treatment of CDI, but this was
mostly due to a key finding that 30-day mortality was significantly lower in first-line treatment
through vancomycin use.21 In a randomized controlled trial (RCT) of CDI first-line treatment
with vancomycin, metronidazole and tolevamer, (Johnson et al. 2014) there were not any notable
differences in CDI recurrence between the vancomycin and metronidazole groups. Interestingly,
tolevamer did have a significantly lower CDI recurrence compared to the other groups.22 It was
hypothesized that tolevamer does not disrupt gut microflora. Still, the use of vancomycin for
first-line treatment had greater clinical success throughout the RCT; as tolevamer and
metronidazole were deemed inferior to vancomycin use.23 As a significant reduction in CDI
recurrence has not been demonstrated from vancomycin use in CDI patients, the 2017
IDSA/SHEA guidelines recommendation of the use of vancomycin for a first recurrence of CDI
is on a basis of a “weak recommendation, low quality of evidence.”24 Some evidence has
emerged that fidaxomicin has a similar cure rate to vancomycin use with a significantly lower
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rate of early recurrence.25 26 Since fidaxomicin use was low in this study, no conclusions can be
made to support this claim, but the role of fidaxomicin in reducing risk of CDI recurrence is
worth further investigation.
Although treatment concordance was not significantly associated with CDI recurrence, a
non-severe epidemiologic classification and increasing age, controlling for all other variables,
increased the probability of recurrence. Increasing susceptibility to disease as age increases may
generally explain the increased risk of recurrent CDI in older age groups. Non-severity as a risk
factor for recurrence is unknown. This is a topic for confirmation in other surveillance sites and,
if confirmed, further investigation. Still, medical providers should pay close attention to patients
who are classified as non-severe and/or elderly due to the increased risk for recurrence in these
groups.
There are several limitations in this study. First, the CT-EIP only detects lab-confirmed
cases. There are likely to be cases with mild disease who do not seek healthcare and some who
do seek healthcare but do not get diagnostic testing specific to CDI. Therefore, these cases are
never captured. Of cases detected in surveillance, only 51.4% of all cases had sufficient data to
be included in analysis and there were significant differences between specific study
characteristics in the non-study sample and study sample. The differences in epidemiologic
classification, age, underlying medical conditions, and previous antibiotic use can be explained
by a general understanding that those who are older, have previous antibiotic use, underlying

25

Cornely, Oliver A., Mark A. Miller, Thomas J. Louie, Derrick W. Crook, and Sherwood L. Gorbach. "Treatment of
first recurrence of Clostridium difficile infection: fidaxomicin versus vancomycin." Clinical infectious diseases 55,
no. suppl_2 (2012): S154-S161.
26
Guery, Benoit, Francesco Menichetti, Veli-Jukka Anttila, Nicholas Adomakoh, Jose Maria Aguado, Karen
Bisnauthsing, Areti Georgopali et al. "Extended-pulsed fidaxomicin versus vancomycin for Clostridium difficile
infection in patients 60 years and older (EXTEND): a randomised, controlled, open-label, phase 3b/4 trial." The
Lancet Infectious Diseases 18, no. 3 (2018): 296-307.Guery B et al. 2017 Lancet Infect Dis 296-307

18
medical conditions, and have a greater number of HCFO or CO-HCFA classifications are more
likely to have a well-documented medical history and therefore complete data. Still, the
differences in completeness of data by gender and race/ethnicity cannot be readily explained.
Further, duration of treatment was defined by what the healthcare provider ordered per
medical chart review by the CT-EIP data abstraction team. In clinical infectious disease, ordering
providers typically prescribe antibiotics in intervals of seven or three days. Since numerous
prescribed treatment periods fall outside of these intervals in this study, the prescribed treatment
durations are particularly unusual, especially durations less than five days. This can partly be
explained by patients who received antibiotic treatment while hospitalized and after being
discharged, as a patient could have received an antibiotic for the finite number of days
hospitalized and an extended duration of treatment while discharged, leading to an
unconventional treatment duration over the course of CDI. As for patients with a duration less
than five days, rationales behind these short durations are unknown. Future CDI surveillance
should consider collecting data on the rationale behind the prescribed treatment regimen,
particularly for duration, from Connecticut providers. Aside from sporadic comments in the
patient charts, rationales for concordant treatment deviation would better inform interventions to
increase concordance. Study characteristics regarding the Connecticut provider such as their age
and specialty could better inform strategies to increase concordance with the guidelines.
Lastly, treatment dosage, route of administration and frequency of dosing were not
included in the definition of guideline concordance, and serum creatinine level was not included
in the severity definition due to these variables being unavailable. Therefore, the definition of the
treatment concordance variable in this study is not as specifically defined to match the true
treatment guidelines.
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This study focused on first-line treatment strategies, but fecal microbiota treatment
(FMT) has emerged as a second-line/alternative treatment strategy for CDI leading to low
recurrence rates CDI.27 For recurrent cases, the 2017 guidelines recommend adjusting the
treatment regimen used from the initial episode as well as suggesting fecal microbiota transplant
(FMT) for patients with multiple (≥3) recurrences. Concordance with these recommendations
could be the subject of another study.
In conclusion, the updated 2017 IDSA/SHEA guidelines that focus on vancomycin as a
first-line treatment in adult patients with CDI have led to a greater proportion of concordant care,
with the highest frequency of CDI concordant care in 2019. Additional analysis of patients who
are non-severe epidemiologic classified, the group with the highest rate of discordance, is needed
to determine what treatment factors may influence recurrence in this group.
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Appendix:
Table 1. Study Characteristics Stratified by Whether Excluded (Incomplete Data) or Included (Complete Data)

Characteristic
Case Classification
Non-severe
Severe
Fulminant
Year
2017
2018
2019
Subsequent Recurrent CDI
Female
Age (Mean ± SD)
Age Group (six categories)
<18
18-44
45-64
65-74
75-84
≥85
Race/Ethnicity~
NH White
NH Black
Hispanic
NH Other/Unk
Epidemiologic Classification+
HCFO
CA
CO-HCFA
Any Underlying Condition
Previous Antibiotic Use
~

Frequency
of Missing
Data

Excluded
(Incomplete Data)
N = 1167

Included
(Complete
Data)
N = 1232

1137

0.882
21 (70.0)
8 (26.7)
1 (3.3)

811 (65.8)
381 (30.9)
40 (3.3)

552

553
552
552
552

0.220
213 (34.6)
239 (38.9)
163 (26.5)
51 (8.3)
403 (65.5)
56.86 ± 22.16

394 (32.0)
465 (37.7)
373 (30.3)
136 (11.0)
725 (58.9)
65.61 ± 19.06

32 (5.2)
134 (21.8)
195 (31.7)
106 (17.2)
91 (14.8)
57 (9.3)

21 (1.7)
146 (11.9)
370 (30.0)
248 (20.1)
247 (20.1)
200 (16.2)

526

0.06
0.006
<0.001
<0.001

<0.001
402 (62.7)
23 (3.6)
52 (8.1)
164 (25.6)

890 (72.2)
147 (11.9)
95 (7.7)
100 (8.1)

18 (2.9)
464 (75.5)
133 (21.6)
253 (41.1)
238 (38.7)

171 (13.9)
606 (49.2)
455 (36.9)
235 (19.1)
328 (26.6)

552

552
552

P+

<0.001

Race: Others/Unknown include those who identify as Pacific Islanders, those who identify as American
Indian/Alaska Native, those who identify as Asian, and Unknown
~
Non-Hispanic (NH)
+
P-value for analysis of variance T-test (continuous variable) or X2 test (categorical variable)

<0.001
<0.001
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Table 2. Description of the Study Population by Year, includes 2013-2016 data from Martinez et al. (2018)

Characteristic
Guideline Concordant Care
Recurrent CDI
Female
Age (Mean ± SD)
Age Group
<20
20-44
45-64
65-74
75-84
≥85
Ethnicity
Hispanic
Non-Hispanic
Other/Unknown
Race
White
Black
Other/Unknown
Case Classification
Non-severe
Severe
Fulminant
First-line Treatment
Vancomycin
Metronidazole
Fidaxomicin
Rifampin
Nitazoxanide
Combination/Unknown+
Epidemiologic Classification
HCFO$
CA$
CO-HCFA$
Any Underlying Condition$
Previous Antibiotic Use$
#

2013-2016
N=1513 (%)*
131 (8.7)
240 (15.9)
935 (61.8)
64 ± 19#

2017
N=391 (%)*
39 (10.0)
43 (11.0)
242 (61.9)
65.89 ± 19.14

2018
N=456 (%)*
105 (23.0)
53 (11.6)
263 (57.7)
65.74 ± 19.10

2019
N=369 (%)*
136 (36.9)
40 (10.8)
211 (57.2)
64.66 ± 19.06

38 (2.5)
205 (13.5)
456 (30.1)
307 (20.3)
283 (18.7)
224 (14.8)

9 (2.3)
41 (10.5)
116 (29.7)
79 (20.2)
79 (20.2)
67 (17.1)

8 (1.8)
56 (12.3)
140 (30.7)
90 (19.7)
83 (18.2)
79 (17.3)

8 (2.2)
45 (12.2)
112 (30.4)
73 (19.8)
82 (22.2)
49 (13.3)

60 (4.0)
1359 (89.8)
94 (6.2)

32 (8.2)
342 (87.5)
17 (4.4)

33 (7.2)
366 (80.3)
57 (12.5)

30 (8.1)
331 (89.7)
8 (2.2)

1166 (77.1)
175 (11.6)
172 (11.4)

296 (75.7)
42 (10.7)
53 (13.6)

316 (69.3)
49 (10.8)
91 (20.0)

282 (76.4)
59 (16.0)
28 (7.6)

1074 (71.0)
415 (27.4)
24 (1.6)

262 (67.0)
114 (29.2)
15 (3.8)

289 (63.4)
153 (33.6)
14 (3.1)

256 (69.4)
102 (27.6)
11 (3.0)

406 (26.8)
902 (59.6)
0 (0.0)
0 (0.0)
0 (0.0)
205 (13.6)

145 (37.1)
223 (57.0)
7 (1.8)
1 (0.3)
3 (0.8)
12 (3.1)

279 (61.2)
174 (38.2)
3 (0.7)
0 (0.0)
0 (0.0)
0 (0.0)

292 (79.1)
72 (19.5)
5 (1.4)
0 (0.0)
0 (0.0)
0 (0.0)

..
..
..
..
..

54 (13.8)
197 (50.4)
140 (35.8)
89 (22.8)
98 (25.1)

74 (16.2)
222 (48.7)
160 (35.1)
93 (20.4)
105 (23.0)

35 (9.5)
185 (50.1)
149 (40.4)
53 (14.4)
125 (33.9)

Mean and standard deviation presented as whole numbers per Martinez et al. (2018)
Other/Unknown values: 2013-2016 values may have complete treatment data but Martinez et al. (2018) did not
explicitly report the treatment regimen for these cases. 2017 cases had equal duration of treatment for two or more
medications therefore leading to Other/Unknown classification.
* % may not sum to 100 % due to rounding.
$
Martinez et al. (2018) did not report epidemiologic classification, underlying condition, previous antibiotic use.
+
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Table 3. Duration of antibiotic treatment (days) by study variables and specific antibiotics.

Characteristic
Year
2017
2018
2019
Age Group
<18
18-44
45-64
65-74
75-84
≥85
Treatment
Vancomycin
Metronidazole
Fidaxomicin
Rifampin
Nitazoxanide
Other
Recurrent CDI
Yes
No
Case Classification
Non-severe
Severe
Fulminant
Epi Classification+
HCFO
CA
CO-HCFA
Gender
Female
Male
Race/Ethnicity~
NH White
NH Black
Hispanic
NH Other/Unk
Underlying Condition
Yes
No
Prev Antibiotic Use
Yes
No
Died in Treatment

Duration+

Unk

≤5

6

7

9

10

11 12 13

14

≥15 Total Mean ± SD

3
0
0

96
112
62

5 9 13 23
10 13 2 36
2 4 6 26

80
118
149

12
14
12

8
7
9

24
20
16

74
67
45

47
66
42

394
465
373

10.12 ± 6.82
10.92 ± 8.95
10.87 ± 7.55

0
0
0
0
2
1

2
26
74
63
56
49

0
1
2
5
7
2

3
12
21
11
20
18

11
47
109
62
61
57

2
3
12
6
8
7

0
2
7
6
7
2

1
8
26
6
11
8

1
21
60
47
34
23

1
18
44
31
34
27

21
146
370
248
247
200

11.00 ± 7.15
10.23 ± 5.52
10.99 ± 8.11
10.65 ± 8.32
10.73 ± 8.62
10.19 ± 7.66

0
3
0
0
0
0

99
162
0
0
0
9

6 9 10 54
11 16 11 28
0 0 0 2
0 0 0 0
0 1 0 0
0 0 0 1

240
96
10
0
0
1

26 19 37 118 114
11 5 22 67 37
0 0 1
0
2
0 0 0
0
1
1 0 0
0
1
0 0 0
1
0

732
469
15
1
3
12

12.20 ± 8.63
8.33 ± 5.99
11.87 ± 5.40
15.00
12.33 ± 6.11
4.25 ± 4.39

0
3

26
244

2 2 1 11
15 24 20 74

48
299

5 0 6 19 16
33 24 54 167 139

136
1096

10.54 ± 6.97
10.67 ± 8.01

2
1
0

143
114
13

10 13 10 63
5 8 10 20
2 5 1 2

266
77
4

25 18 42 126
11 5 18 58
2 1 0
2

93
54
8

811
381
40

11.07 ± 8.02
9.92 ± 7.64
9.23 ± 7.37

1
1
1

42
121
107

2
8
7

5 4 15
11 11 38
10 6 32

30
200
117

5 4 9
14 12 33
19 8 18

27
91
68

27
66
62

171
606
455

11.06 ± 9.20
10.50 ± 7.14
10.70 ± 8.34

2
1

163
107

9
8

14 12 52
12 9 33

211
136

20 11 34 120
18 13 26 66

77
78

725
507

10.51 ± 7.86
10.85 ± 7.96

3
0
0
0

187
30
22
31

10 20 12 60
6 3 5 10
0 2 3 6
1 1 1 9

268
33
20
26

24 17 37 135 117
6 4 11 20 19
5 2 7 18 10
3 1 5 13
9

890
147
95
100

10.82 ± 7.99
10.94 ± 8.69
9.93 ± 6.01
9.48 ± 7.40

0
3

46
224

0 5 5 21
17 21 16 64

75
272

7 2 12 39 23
31 22 48 147 132

235
997

10.47 ± 6.94
10.70 ± 8.11

1
2
0

60
210
41

5 6 5 16
12 20 16 69
0 2 2 2

102
245
4

7 8 18 54 46
31 16 42 132 109
0 0 0
1
5

328
904
57

11.24 ± 7.93
10.44 ± 7.88
5.11 ± 5.11

0
4
8
8
3
3

8

0
4
7
3
4
3

23
+

Unknown duration: Although duration is missing, enough data exists from first-line treatment to designate these as
discordant; Duration of 0: started and stopped medication on same day
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Figure 1. Concordance with selected treatment criteria by year, 2017-2019
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Table 4. Description of Adult Cases by Severity (Initial Episode), 2017-2019

Characteristic
Guideline Concordant Care
Recurrent CDI
Female
Year
2017
2018
2019
Age (Mean ± SD)
Age Group (five categories)
18-44
45-64
65-74
75-84
≥85
Race/Ethnicity~
NH White
NH Black
Hispanic
NH Other/Unk
Epidemiologic Classification+
HCFO
CA
CO-HCFA
Any Underlying Condition
Any Previous Antibiotic Use

Non-Severe
(N=790)
180 (22.8)
101 (12.8)
476 (60.3)

Severe
(N=368)
65 (17.7)
32 (8.7)
210 (57.1)

Fulminant
(N=37)
23 (62.2)
2 (5.4)
18 (48.7)

256 (32.4)
283 (35.8)
251 (31.8)
65.18 ± 17.83

114 (31.0)
152 (41.3)
102 (27.7)
68.43 ± 17.82

14 (37.8)
13 (35.1)
10 (27.0)
72.57 ± 15.33

100 (12.7)
277 (35.1)
142 (18.0)
158 (20.0)
113 (14.3)

43 (11.7)
87 (23.6)
87 (23.6)
78 (21.2)
73 (19.8)

3 (8.1)
4 (10.8)
13 (35.1)
8 (21.6)
9 (24.3)

563 (71.3)
106 (13.4)
65 (8.2)
56 (7.1)

276 (75.0)
32 (8.7)
24 (6.5)
36 (9.8)

27 (73.0)
4 (10.8)
3 (8.1)
3 (8.1)

P+
<0.001
0.064
0.257
0.391

0.002
<0.001

0.205

<0.001
81 (10.3)
425 (53.8)
284 (36.0)
154 (19.5)
250 (31.7)

73 (19.8)
150 (40.8)
145 (39.4)
65 (17.7)
63 (17.1)

8 (21.6)
15 (40.5)
14 (37.8)
4 (10.8)
9 (24.3)

0.349
<0.001

*Percentages may not sum to 100% due to rounding.
~
Race/Ethnicity: Because the majority of those who identified as Hispanic did not identify in a race classification
and a small portion of those identifying as Hispanic identified with a race classification, this variable encompasses
all those who identified as Hispanic without regard to race classification.
+
P-value for analysis of variance F-test (continuous variable) or X2 test (categorical variable)
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Table 5. Unadjusted associations between study variables and 2017 IDSA/SHEA Concordant Treatment Care in
Adults, 2017-2019

Characteristic
Recurrent CDI
Year
2017
2018
2019
Female
Age (Mean ± SD)
Age Group (five categories)
18-44
45-64
65-74
75-84
≥85
Race/Ethnicity~
NH White
NH Black
Hispanic
NH Other/Unk
Case Classification
Non-severe
Severe
Fulminant
Epidemiologic Classification
HCFO
CA
CO-HCFA
Any Underlying Condition
Any Previous Antibiotic Use

135

N (%) With
Concordant
Care
100 (74.1)

384
448
363
704
..

34 (12.7)
101 (37.7)
133 (49.6)
153 (21.7)
67.04 ± 17.64

1.00
3.00 (1.98, 4.54)
5.95 (3.94, 8.99)
0.91 (0.69, 1.20)

146
368
242
244
195

32 (21.9)
78 (21.2)
58 (24.0)
51 (20.9)
49 (25.1)

1.00
0.96 (0.60, 1.53)
1.12 (0.69, 1.83)
0.94 (0.57, 1.55)
1.20 (0.72, 1.99)

866
142
92
95

211 (24.4)
29 (20.4)
12 (13.0)
16 (16.8)

1.00
0.80 (0.52, 1.23)
0.47 (0.25, 0.87)
0.63 (0.36, 1.10)

790
368
37

180 (22.8)
65 (17.7)
23 (62.2)

1.00
0.73 (0.53, 1.00)
5.57 (2.81, 11.04)

162
590
443
223
322

30 (18.5)
136 (23.1)
102 (23.0)
46 (20.6)
72 (22.4)

1.00
1.32 (0.85, 2.05)
1.32 (0.84, 2.07)
0.88 (0.61, 1.26)
1.00 (0.73, 1.35)

N*

* Numbers may not sum to total due to missing data
+
Odds of having concordant care compared to having discordant care.

OR+ (95% CI)
1.24 (0.82, 1.88)
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Table 6. Unadjusted Associations between study variables and CDI Recurrence (≥ 18 Years Old), 2017-2019

Characteristic
Guideline Concordant Care
Yes
No
Female
Year
2017
2018
2019
Age (Mean ± SD)
Age Group (five categories)
18-44
45-64
65-74
75-84
≥85
Race/Ethnicity~
NH White
NH Black
Hispanic
NH Other/Unk
Case Classification
Non-severe
Severe
Fulminant
Epidemiologic Classification
HCFO
CA
CO-HCFA
Any Underlying Condition
Any Previous Antibiotic Use

N*

N (%) With
CDI Recurrence

268
927
704

OR (95% CI)

35 (13.1) 1.00
100 (10.8) 0.81 (0.53, 1.22)
82 (11.7) 1.09 (0.76, 1.57)

384
448
363
..

43 (11.2)
52 (11.6)
40 (11.0)
70.06 ± 16.48

1.00
1.04 (0.68, 1.60)
0.98 (0.62, 1.55)
..

146
368
242
244
195

9 (6.2)
36 (9.8)
30 (12.4)
33 (13.5)
27 (13.9)

1.00
1.65 (0.77, 3.52)
2.15 (0.99, 4.68)
2.38 (1.11, 5.13)
2.45 (1.11, 5.38)

866
142
92
95

108 (12.5)
12 (8.5)
9 (9.8)
6 (6.3)

1.00
0.65 (0.35, 1.21)
0.76 (0.37, 1.56)
0.47 (0.20, 1.11)

790
368
37

101 (12.8) 1.00
32 (8.7) 0.65 (0.43, 0.99)
2 (5.4) 0.39 (0.09, 1.65)

162
590
443
223
322

16 (9.9)
62 (10.5)
57 (12.9)
24 (10.8)
28 (8.7)

1.00
1.07 (0.60, 1.91)
1.35 (0.75, 2.42)
0.94 (0.59, 1.49)
0.68 (0.44, 1.06)

* Percentages may not sum to 100% due to rounding.
Table 7. Multivariable Logistic Regression between study variables and CDI Recurrence in Adults , 2017-2019

Characteristic
Discordant Care
Age (Mean ± SD)
Case Classification
Non-severe
Severe
Fulminant

Adjusted OR^
(95% CI)
0.80 (0.53, 1.21)
1.02 (1.01, 1.03)

0.288
0.006

1.00
0.63 (0.41, 0.95)
0.32 (0.08, 1.37)

..
0.029
0.126

* Numbers may not sum to total due to missing data
†
P-value for analysis of variance Likelihood-Ratio X2

P†
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^

Adjusting for sex, year, age, race/ethnicity, case classification, epidemiologic classification, any underlying
medical conditions, any previous antibiotic use. Study characteristics with a significant p-value for X2 remained in
model
Table 8. Secondary Treatment Permutations for Unadjusted Associations between Study Variables and CDI
Recurrence (≥ 18 Years Old), 2017-2019

Characteristic
Guideline Concordant Care
Yes
No
Concordant Antibiotic
Yes
No (metronidazole)
Those on Concordant Antibiotic
Duration 10 days
Duration <10 days
Duration >10 days
Those on Metronidazole
Duration 10 days
Duration <10 days
Duration >10 days
Those on Concordant Antibiotic
Duration 10 days
Duration ≤5 days
Duration 6-9 days
Duration 11-14 days
Duration ≥15 days
Those on Metronidazole
Duration 10 days
Duration ≤5 days
Duration 6-9 days
Duration 11-14 days
Duration ≥15 days

N*

N (%) With
CDI Recurrence

OR (95% CI)

268
927

35 (13.1) 1.00
100 (10.8) 0.81 (0.53, 1.22)

707
457

83 (11.7) 1.00
50 (10.9) 0.92 (0.64, 1.34)

236
160
311

33 (14.0) 1.00
21 (13.1) 0.93 (0.52, 1.67)
29 (9.3) 0.63 (0.37, 1.08)

89
228
140

14 (15.7) 1.00
20 (8.8) 0.52 (0.25, 1.07)
16 (11.4) 0.69 (0.32, 1.50)

236
83
77
198
113

33 (14.0)
11 (13.3)
10 (13.0)
19 (9.6)
10 (8.9)

1.00
0.94 (0.45, 1.96)
0.92 (0.43, 1.96)
0.65 (0.36, 1.19)
0.60 (0.28, 1.26)

89
163
65
103
37

14 (15.7)
15 (9.2)
65(7.7)
10 (9.7)
6 (16.2)

1.00
0.54 (0.25, 1.18)
0.45 (0.15, 1.31)
0.58 (0.24, 1.37)
1.04 (0.37, 2.95)

